부산대학교 도서관

The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI therapies. Intrinsic and acquired resistance to ICIs has focused research towards new combination therapy approaches that seek to increase response rates, the depth of remission and the durability of benefit. In this Review, we describe how radiotherapy, through its immunomodulating effects, represents a promising combination partner with ICIs. We describe how recent research on DNA damage response (DDR) inhibitors in combination with radiotherapy may be used to augment this approach. Radiotherapy can kill cancer cells while simultaneously triggering the release of pro-inflammatory mediators and increasing tumour-infiltrating immune cells - phenomena often described colloquially as turning immunologically 'cold' tumours 'hot'. Here, we focus on new developments illustrating the key role of tumour cell-autonomous signalling after radiotherapy. Radiotherapy-induced tumour cell micronuclei activate cytosolic nucleic acid sensor pathways, such as cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING), and propagation of the resulting inflammatory signals remodels the immune contexture of the tumour microenvironment. In parallel, radiation can impact immunosurveillance by modulating neoantigen expression. Finally, we highlight how tumour cell-autonomous mechanisms might be exploited by combining DDR inhibitors, ICIs and radiotherapy. This Review focuses on the role of tumour cell-autonomous signalling after radiotherapy. It describes how radiotherapy, through its immunomodulating effects, might be combined with immune checkpoint inhibitors and other immunotherapies and how DNA damage response inhibitors in combination with radiotherapy may be used to further augment this approach.
Author(s): Martin McLaughlin [sup.1] , Emmanuel C. Patin [sup.1] , Malin Pedersen [sup.2] , Anna Wilkins [sup.3] , Magnus T. Dillon [sup.1] [sup.3] , Alan A. Melcher [sup.2] [sup.3] , [...]